TuHURA Biosciences (HURA) CFO awarded 1,531,367 stock options at $1.02

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. (HURA) reported that its Chief Financial Officer, Dan Dearborn, received stock options to purchase 1,531,367 shares of common stock at an exercise price of $1.02 per share on 12/12/2025.

The options are held directly, expire on 12/12/2035, and cover 1,531,367 underlying shares, which is also the number of derivative securities beneficially owned after the transaction. One-third of the stock options becomes exercisable on each of the first, second, and third anniversaries of 12/12/2025, creating a three-year vesting schedule.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dearborn Dan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	1,531,367	$0.00	--

Holdings After Transaction: Options (Right to Buy) — 1,531,367 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dearborn Dan

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.02	12/12/2025		A		1,531,367		(1)	12/12/2035	Common Stock	1,531,367	$0	1,531,367	D

Explanation of Responses:

1. One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025.

	/s/ Dan Dearborn	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TuHURA Biosciences (HURA) disclose in this Form 4?

The company disclosed that its Chief Financial Officer, Dan Dearborn, was granted 1,531,367 stock options to purchase TuHURA Biosciences common stock at an exercise price of $1.02 per share on 12/12/2025.

How many TuHURA Biosciences (HURA) stock options were granted to the CFO and at what exercise price?

The CFO received 1,531,367 stock options with an exercise price of $1.02 per share, giving him the right to buy the same number of TuHURA Biosciences common shares.

When do Dan Dearborns TuHURA Biosciences (HURA) stock options vest?

One-third of the stock options becomes exercisable on the first, second, and third anniversaries of 12/12/2025, resulting in a three-year vesting schedule.

When do the TuHURA Biosciences (HURA) CFO stock options expire?

The stock options granted to the CFO expire on 12/12/2035, after which any unexercised options can no longer be used to purchase TuHURA Biosciences common stock.

How many derivative securities does the TuHURA Biosciences (HURA) CFO own after this grant?

Following the reported transaction, the CFO beneficially owns 1,531,367 derivative securities (stock options), all held directly.

What class of TuHURA Biosciences (HURA) stock underlies the CFOs options?

The options are over TuHURA Biosciences common stock, with 1,531,367 underlying shares tied to the stock option grant.

Is this TuHURA Biosciences (HURA) Form 4 filed for one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, covering the transactions of CFO Dan Dearborn only.